Compare Abbott Laboratories (ABT) vs Freeport-McMoRan Inc (FCX) Price & Performance

Abbott Laboratories (ABT) trades at $111.27, up 1.39% on the day, with strong analyst support (76% buy ratings) and a consensus price target of $120.70. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue growth remains steady at $44.33B for 2025, with solid profitability metrics including 56.61% gross margin and 11.65% net income margin. Recent corporate developments include CE Mark approval for innovative dual glucose-ketone sensors and positive ACS guideline updates for Cologuard cancer screening.

The outlook remains positive with Wall Street consensus favoring accumulation, though risks include potential earnings volatility and competitive pressures in medical technology. The current valuation at 35.89 P/E appears reasonable given the company's innovation pipeline and market leadership. Upside potential exists toward the $120-134 analyst target range, supported by strong cash flow generation and dividend stability.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.